GlassScriptPhysician profile
Asha Vishnagara
NPI 1740420926
$4,389.17
in general payments reported to CMS, 2019-2025
31 companies · $854 in 2025
The $854 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $749 · 2023: $701 · 2024: $1,166 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,364.57 | 2021-2025 | Xtampza, Belbuca |
| Pfizer INC. | $472.11 | 2023-2025 | |
| Abbvie INC. | $438.39 | 2021-2025 | |
| Saluda Medical Americas, INC. | $435.37 | 2024-2025 | Evoke |
| Abbott Laboratories | $171.73 | 2021-2025 | Proclaim |
| Averitas Pharma INC. | $165.29 | 2024-2025 | Qutenza |
| Nevro Corp. | $154.71 | 2021-2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $152.65 | 2022 | |
| Medtronic, INC. | $110.60 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Boston Scientific Corporation | $91.15 | 2021-2022 | |
| Nalu Medical, INC. | $88.67 | 2021-2024 | Nalu Neurostimulation System |
| Lilly USA, LLC | $76.89 | 2021-2022 | |
| Tersera Therapeutics LLC | $73.86 | 2024-2025 | Prialt |
| Allergan, INC. | $66.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $64.89 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.58 | 2021-2022 | |
| Ibsa Pharma INC. | $50.16 | 2021-2024 | Licart, Tirosint, Flector |
| Amneal Pharmaceuticals LLC | $38.99 | 2023 | Lyvispah |
| Scilex Pharmaceuticals INC. | $36.05 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $34.91 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.33 | 2021-2025 | Relistor |
| Virtus Pharmaceuticals LLC | $31.41 | 2021 | |
| Arbor Pharmaceuticals, INC. | $29.80 | 2021 | |
| Merz Pharmaceuticals, LLC | $26.55 | 2022 | |
| Spr Therapeutics, INC | $20.61 | 2025 | Sprint Pns System |
| Bioventus LLC | $19.74 | 2024 | Durolane |
| Redhill Biopharma INC. | $17.87 | 2021 | |
| Almatica Pharma LLC | $16.67 | 2021 | |
| Valinor Pharma, LLC | $16.64 | 2025 | Movantik |
| Pacira Pharmaceuticals Incorporated | $14.34 | 2025 | Iovera, Zilretta |
| Eisai INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Vishnagara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.